CHRM1: Muscarinic acetylcholine receptor M1
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.
- Drugs that act on it: 32
- Approved: 28
- In phases 1 to 3: 4
- Sponsors: 20
Who is on it, and how far along
Every drug ChEMBL records acting on CHRM1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 31
- Other 1
Approved28
- Atropine
- Xanomeline
- Glycopyrronium
- Scopolamine
- Pilocarpine
- Trihexyphenidyl
- Benztropine
- Biperiden
- Dicyclomine
- Minaprine
- Oxyphenonium
- Procyclidine
- Anisotropine
- Cevimeline
- Clidinium
- Cycrimine
- Diphemanil
- Diphenidol
- Ethopropazine
- Hexocyclium
- Isopropamide
- Mepenzolate
- Methixene
- Methscopolamine
- Oxyphencyclimine
- Pirenzepine
- Propantheline
- Tridihexethyl
Phase 30
Phase 24
Phase 10
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Pfizer516%
- Merck & Co. (MSD)26%
- Novartis Pharmaceuticals26%
- Takeda Pharmaceuticals USA26%
- AbbVie13%
- Alcon13%
- Asmacure Ltée13%
- AstraZeneca Pharmaceuticals13%
- Baxter International13%
- Boehringer Ingelheim Pharmaceuticals13%
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 25 of 32 act as: Muscarinic acetylcholine receptor M1 antagonist; the rest name their own mechanism.| Atropine | Approved | Magna Pharmaceuticals, Inc. | Small molecule | Antagonist | 83 |
| Xanomeline | Approved | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Small molecule | AgonistMuscarinic acetylcholine receptor M1 agonist | 29 |
| Glycopyrronium | Approved | Journey Medical | Small molecule | Antagonist | 22 |
| Scopolamine | Approved | Baxter International | Small molecule | Antagonist | 18 |
| Pilocarpine | Approved | Alcon | Small molecule | AgonistMuscarinic acetylcholine receptor M1 agonist | 8 |
| Trihexyphenidyl | Approved | Pfizer | Small molecule | Antagonist | 4 |
| Benztropine | Approved | Merck & Co. (MSD) | Small molecule | Antagonist | 3 |
| Biperiden | Approved | — | Small molecule | Antagonist | 1 |
| DicyclomineWithdrawn | Approved | AbbVie | Small molecule | Antagonist | 1 |
| MinaprineWithdrawn | Approved | AstraZeneca Pharmaceuticals | Small molecule | AgonistMuscarinic acetylcholine receptor M1 agonist | 1 |
| Oxyphenonium | Approved | Novartis Pharmaceuticals | Small molecule | Antagonist | 1 |
| Procyclidine | Approved | Pfizer | Small molecule | Antagonist | 1 |
| Anisotropine | Approved | — | Small molecule | Antagonist | 0 |
| Cevimeline | Approved | Cosette Pharmaceuticals | Small molecule | AgonistMuscarinic acetylcholine receptor M1 agonist | 0 |
| Clidinium | Approved | Roche | Small molecule | Antagonist | 0 |
| Cycrimine | Approved | Eli Lilly | Small molecule | Antagonist | 0 |
| Diphemanil | Approved | — | Small molecule | Antagonist | 0 |
| Diphenidol | Approved | GSK | Small molecule | Antagonist | 0 |
| Ethopropazine | Approved | Pfizer | Small molecule | Antagonist | 0 |
| Hexocyclium | Approved | — | Small molecule | Antagonist | 0 |
| Isopropamide | Approved | — | Small molecule | Antagonist | 0 |
| Mepenzolate | Approved | Sanofi | Small molecule | Antagonist | 0 |
| Methixene | Approved | Novartis Pharmaceuticals | Small molecule | Antagonist | 0 |
| Methscopolamine | Approved | Sandoz | Small molecule | Antagonist | 0 |
| Oxyphencyclimine | Approved | Pfizer | Small molecule | Antagonist | 0 |
| Pirenzepine | Approved | WinSanTor, Inc | Small molecule | Antagonist | 0 |
| Propantheline | Approved | Takeda Pharmaceuticals USA | Small molecule | Antagonist | 0 |
| Tridihexethyl | Approved | Pfizer | Small molecule | Antagonist | 0 |
| ASM-024 | Phase 2 | Asmacure Ltée | Other | Antagonist | 0 |
| MK-7622 | Phase 2 | Merck & Co. (MSD) | Small molecule | Positive allosteric modulatorMuscarinic acetylcholine receptor M1 positive allosteric modulator | 0 |
| TAK-071 | Phase 2 | Takeda Pharmaceuticals USA | Small molecule | Positive allosteric modulatorMuscarinic acetylcholine receptor M1 positive allosteric modulator | 0 |
| Talsaclidine | Phase 2 | Boehringer Ingelheim Pharmaceuticals | Small molecule | AgonistMuscarinic acetylcholine receptor M1 agonist | 0 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 50 in all, from ClinicalTrials.gov.Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Parkinson disease
- 0.67
- Myopia
- 0.59
- Asthma
- 0.59
- Gastrointestinal disease
- 0.58
- Peptic ulcer disease
- 0.58
- Hyperhidrosis
- 0.56
- Mydriasis
- 0.55
- Nausea
- 0.54
- Xerostomia
- 0.54
Genes and related targets
Complexes and families that share a gene with this target- Genes
- CHRM1
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL216, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P11229, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets